2026-11-02

Oracle Breaks Its Own 'No More Bonds This Year' Promise With Another $20 Billion Raise - Stock Drops 6.2%, While CoreWeave and Microsoft Hold Up

Written & reviewed by the TradeSmrt editorial team · 2026-11-02

In this article

What Happened
Why a Smaller Raise Triggered a Bigger Reaction
Same AI-Debt Story, Different Day - Why CoreWeave and Microsoft Didn't Follow Oracle Down
What to Take Away From This
FAQ
Sources

What Happened

Before the opening bell on Monday, November 2, Oracle (NYSE: ORCL) filed paperwork with the SEC for a large new capital raise. The company is selling $10 billion in new common stock while separately placing $10 billion in senior notes split across six tranches maturing between 2029 and 2046 - five fixed-rate tranches and one floating-rate tranche. The two deals are structured as legally independent offerings, meaning either one can close without the other. Combined, the package totals $20 billion.

Oracle described the use of proceeds in broad terms typical of these filings: general corporate purposes, including capital expenditures, repayment of existing debt, acquisitions, dividends, and share buybacks. That kind of catch-all language is standard boilerplate in offering documents, but it also means investors have little visibility into exactly how the new cash will be allocated. Based on preliminary prospectus estimates and Friday's (Oct. 30) closing price of $130.67, the equity piece could amount to roughly 76.5 million new shares, though final pricing and size still depend on the bookbuilding process.

The market's reaction was immediate and negative. Oracle shares fell 6.2% to $122.61 in Monday trading, their lowest level in more than three months. The stock opened down roughly 4% and the decline widened to 6% as the session progressed, with heavier-than-usual volume suggesting the selling wasn't a knee-jerk reaction from a handful of traders but a broader repositioning among institutional holders.

What makes the timing notable is that Oracle explicitly said it wouldn't be doing this. Back in February, the company unveiled a plan to raise $45 billion to $50 billion over the course of 2026 - a $20 billion at-the-market equity program, a $25 billion bond sale (which drew a record-setting $129 billion in investor orders), and a $5 billion mandatory convertible preferred offering. At the time, Oracle said explicitly that it did not expect to issue additional bonds for the remainder of 2026. Nine months later, that's exactly what it's doing: a fresh $10 billion bond sale that falls outside the plan it laid out at the start of the year.

Why a Smaller Raise Triggered a Bigger Reaction

On pure dollar terms, this $20 billion raise is less than half the size of February's $45-50 billion program. Yet the stock reaction was sharper - 6.2% this time versus 2.8% back in February. That gap comes down to how markets price surprise versus a pre-announced plan. February's raise was framed from the start as "here's what we're doing this year," so the market had already absorbed the number before it happened. This raise is different: it's an addition on top of a plan Oracle had already drawn a line under, breaking a specific commitment management had made just months earlier. What spooks investors most isn't the headline dollar figure - it's the signal that a company's own guidance can't be relied on. Once that trust is broken, markets start pricing in uncertainty about how much more might be needed next quarter, and that uncertainty discount tends to weigh on the stock more heavily than the raise itself would.

The underlying math explains why Oracle keeps coming back to capital markets. The company's fiscal Q1 2027 earnings in September disclosed remaining performance obligations (RPO) - its contracted backlog - of $664 billion, a figure that reflected enormous demand but also implied an enormous buildout bill: turning that backlog into revenue requires building and powering data centers and GPU clusters years ahead of when the cash actually arrives. Oracle's annual capital spending runs somewhere around $70 billion, a level its operating cash flow alone can't cover. The company has been bridging that gap by repeatedly tapping both equity and debt markets - and what used to look like a one-time financing event is increasingly looking like a standing cycle investors now expect to recur every few quarters.

There's a credit dimension here too. Each additional bond sale adds to Oracle's total debt load and interest burden, and if that burden grows faster than revenue and earnings, rating agencies could eventually revisit their outlook. A downgrade would raise the interest rate Oracle pays on its next bond sale, creating a reinforcing loop. Oracle's rating still sits comfortably in investment-grade territory, but the market's sharp reaction to what it read as a broken promise suggests investors are already trying to price in that risk before it shows up in an actual ratings action.

Same AI-Debt Story, Different Day - Why CoreWeave and Microsoft Didn't Follow Oracle Down

The notable detail from Monday is that Oracle moved alone. CoreWeave, the AI data-center leasing specialist, gained nearly 2%, and Microsoft barely budged. All three names sit under the same broad "AI buildout funded by debt" umbrella, yet the stock reactions split in opposite directions.

The difference comes down to how - and how often - each company has to tap the debt markets. CoreWeave has already spent much of this year under a cloud of credit concern, with its bond spreads widening and credit-default-swap pricing climbing earlier in the year. With expectations already reset that low, a day with no fresh bad news is often enough to produce a small bounce. Microsoft sits at the opposite end: decades of cloud and software cash flow give it enormous internal funding capacity, so even under the same AI-capex narrative, it simply doesn't need to lean on external capital the way Oracle does - and investors price it accordingly.

Oracle sits in the middle. Its revenue and backlog have scaled to Big Tech size, but its cash-generating capacity hasn't caught up, and Monday made that gap unusually visible by forcing Oracle to break a specific promise to close it. Combined with Alphabet's roughly 12% single-day crash on capex fears in late October and Amazon's guidance miss despite 39% AWS growth, the pattern across this earnings season is becoming clear: how a company funds its AI buildout, not just how fast that buildout is growing, is now one of the biggest swing factors in how Big Tech and AI-infrastructure stocks trade.

What to Take Away From This

A company's own guidance functions as a promise to investors. Reversing a specific commitment - "we won't issue more bonds this year" - tends to damage credibility regardless of the dollar size involved. Tracking whether management's words match its later actions, quarter after quarter, often matters more than the headline numbers themselves.
Simultaneous stock-and-bond offerings can signal urgency. If one financing tool were sufficient, there'd be little reason to use two at once. A rising frequency of combined raises points to a structural, not temporary, gap between a company's cash generation and its capital spending needs.
Compare backlog growth against the cash flow needed to fund it without external financing. A growing order backlog is good news on its own, but the more important question is where the money to fulfill those orders is actually coming from.
Within the same sector and macro theme, balance-sheet strength still separates winners from losers. Rather than treating an entire sector as one trade, check each company's cash flow statement and how often it returns to capital markets.
Dilution and interest costs accumulate even when a single raise feels small. A dilution rate that's barely noticeable in isolation compounds when the same pattern repeats, with real long-term effects on earnings per share and dividend capacity.

FAQ

Why does Oracle sell stock and bonds at the same time instead of picking one?

Stock sales carry no interest cost but dilute existing shareholders, while bonds avoid dilution but add a fixed annual interest burden. Using both spreads the financial cost across two different mechanisms rather than relying entirely on one. That said, needing to use both tools repeatedly is itself a signal that the capital requirement is large and pressing.

How much will this dilute existing Oracle shareholders?

Based on preliminary estimates using Friday's $130.67 close, roughly 76.5 million new shares could be issued, representing a dilution of existing shares outstanding by a corresponding percentage. The exact dilution won't be confirmed until final pricing and share counts are set once the offering closes.

Why does it matter that Oracle keeps going back to capital markets?

Oracle's $664 billion order backlog is a genuine growth driver, but converting it into revenue requires massive upfront spending on data centers and GPUs. As long as operating cash flow can't cover that spending on its own, the company has to keep raising external capital, and each round adds to shareholder dilution and interest costs. The real concern isn't any single raise - it's that the pattern keeps repeating, which raises doubts about how quickly that backlog will actually convert into profitable revenue.

Sources

This article is an original analysis synthesizing the reporting below, not a reproduction of the original articles. Please check the primary sources directly for the most current figures and statements.

⚠️ This article is for informational purposes only and does not constitute investment advice. Market conditions change constantly, so please verify the latest information before making any investment decisions.